- Home
- WATT vs KPRX Comparison
WATT vs KPRX Comparison
Compare WATT & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- KPRX
- Stock Information
- Founded
- WATT 2012
- KPRX 1998
- Country
- WATT United States
- KPRX United States
- Employees
- WATT N/A
- KPRX N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- WATT Technology
- KPRX Health Care
- Exchange
- WATT Nasdaq
- KPRX Nasdaq
- Market Cap
- WATT 10.0M
- KPRX 12.0M
- IPO Year
- WATT 2014
- KPRX N/A
- Fundamental
- Price
- WATT $0.48
- KPRX $3.87
- Analyst Decision
- WATT Strong Buy
- KPRX Strong Buy
- Analyst Count
- WATT 2
- KPRX 1
- Target Price
- WATT $2.25
- KPRX $10.00
- AVG Volume (30 Days)
- WATT 18.4M
- KPRX 42.9K
- Earning Date
- WATT 11-12-2024
- KPRX 11-08-2024
- Dividend Yield
- WATT N/A
- KPRX N/A
- EPS Growth
- WATT N/A
- KPRX N/A
- EPS
- WATT N/A
- KPRX 1.69
- Revenue
- WATT $431,184.00
- KPRX $16,020,000.00
- Revenue This Year
- WATT $95.75
- KPRX N/A
- Revenue Next Year
- WATT $834.07
- KPRX N/A
- P/E Ratio
- WATT N/A
- KPRX $2.29
- Revenue Growth
- WATT N/A
- KPRX N/A
- 52 Week Low
- WATT $0.28
- KPRX $3.00
- 52 Week High
- WATT $2.75
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- WATT 46.32
- KPRX 58.55
- Support Level
- WATT $0.49
- KPRX $3.10
- Resistance Level
- WATT $1.44
- KPRX $4.13
- Average True Range (ATR)
- WATT 0.22
- KPRX 0.26
- MACD
- WATT -0.06
- KPRX 0.04
- Stochastic Oscillator
- WATT 1.55
- KPRX 74.76
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.